{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:30:21Z","timestamp":1791225021409,"version":"4.1.0"},"reference-count":40,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32HL007093"],"award-info":[{"award-number":["5T32HL007093"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32HL007093"],"award-info":[{"award-number":["5T32HL007093"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["NCT02488759"],"award-info":[{"award-number":["NCT02488759"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA015704"],"award-info":[{"award-number":["P30 CA015704"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0396-9","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T03:09:33Z","timestamp":1535684973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report"],"prefix":"10.1136","volume":"6","author":[{"given":"Jacob","family":"Appelbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph B.","family":"Hiatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Steinbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Marc","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nghiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj P.","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3816-2238","authenticated-orcid":false,"given":"Shailender","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,8,31]]},"reference":[{"key":"396_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","volume":"34","author":"SH Baumeister","year":"2016","unstructured":"Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 2016;34:539\u201373.","journal-title":"Annu Rev Immunol"},{"key":"396_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/annonc\/mdx442","volume":"28","author":"AKS Salama","year":"2017","unstructured":"Salama AKS, Moschos SJ. Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. Ann Oncol. 2017;28:57\u201374.","journal-title":"Ann Oncol"},{"key":"396_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","volume":"57","author":"JC Hassel","year":"2017","unstructured":"Hassel JC, Heinzerling L, Aberle J, B\u00e4hr O, Eigentler TK, Grimm M-O, et al. Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017;57:36\u201349.","journal-title":"Cancer Treat Rev"},{"key":"396_CR4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","volume":"60","author":"L Hofmann","year":"2016","unstructured":"Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190\u2013209.","journal-title":"Eur J Cancer"},{"key":"396_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"key":"396_CR6","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1714\u201368.","journal-title":"J Clin Oncol"},{"key":"396_CR7","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non\u2013small-cell lung cancer. N Engl J Med. 2015;372:2018\u201328.","journal-title":"N Engl J Med"},{"key":"396_CR8","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333.","journal-title":"N Engl J Med"},{"key":"396_CR9","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar AV, Castellano D, O\u2019Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483\u201392.","journal-title":"Lancet Oncol"},{"key":"396_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung Cancer. N Engl J Med. 2015;373:123\u201335.","journal-title":"N Engl J Med"},{"key":"396_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375\u201384.","journal-title":"Lancet Oncol."},{"key":"396_CR12","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332.","journal-title":"N Engl J Med"},{"key":"396_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"396_CR14","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","volume":"18","author":"PA Ascierto","year":"2017","unstructured":"Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, et al. Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017;18:611\u201322.","journal-title":"Lancet Oncol."},{"key":"396_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122\u201333.","journal-title":"N Engl J Med"},{"key":"396_CR16","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O\u2019Day S, Weber J, Garbe C, et al. Ipilimumab plus Dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517\u201326.","journal-title":"N Engl J Med"},{"key":"396_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","volume":"45","author":"TK Eigentler","year":"2016","unstructured":"Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Gr\u00fcnwald V, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7\u201318.","journal-title":"Cancer Treat Rev"},{"key":"396_CR18","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749\u201355.","journal-title":"N Engl J Med"},{"key":"396_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210\u201325.","journal-title":"Eur J Cancer"},{"key":"396_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/CJI.0b013e318193a206","volume":"32","author":"S Bhatia","year":"2009","unstructured":"Bhatia S, Huber BR, Upton MP, Thompson JA. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother. 2009;32:203\u20135.","journal-title":"J Immunother"},{"key":"396_CR21","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/cncr.30475","volume":"123","author":"KG Paulson","year":"2017","unstructured":"Paulson KG, Lewis CW, Redman MW, Simonson WT, Lisberg A, Ritter D, et al. Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: a prospective validation study. Cancer. 2017;123:1464\u201374.","journal-title":"Cancer"},{"key":"396_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/dvg.20365","volume":"46","author":"DT Page","year":"2008","unstructured":"Page DT, Olofsson B. Multiple roles for apoptosis facilitating condensation of theDrosophila ventral nerve cord. Genesis. 2008;46:61\u20138.","journal-title":"Genesis"},{"key":"396_CR23","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1172\/JCI90962","volume":"127","author":"V Afshar-Kharghan","year":"2017","unstructured":"Afshar-Kharghan V. The role of the complement system in cancer. J Clin Invest. 2017;127:780\u20139.","journal-title":"J Clin Invest"},{"key":"396_CR24","doi-asserted-by":"crossref","unstructured":"Niv G, Grinberg T, Waserberg N, Dickman R, Niv Y. Perforation and mortality after cleansing enema for acute constipation are not rare but are preventable. Int J Gen Med. 2013;2013(6):323\u20138.","DOI":"10.2147\/IJGM.S44417"},{"key":"396_CR25","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jpainsymman.2010.01.011","volume":"40","author":"AC Mackey","year":"2010","unstructured":"Mackey AC, Green L, Greene P, Avigan M. Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manag. 2010;40:e1\u20133.","journal-title":"J Pain Symptom Manag"},{"key":"396_CR26","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1093\/annonc\/mdx403","volume":"28","author":"M Collins","year":"2017","unstructured":"Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol. 2017;28:2860\u20135.","journal-title":"Ann Oncol"},{"key":"396_CR27","doi-asserted-by":"crossref","unstructured":"Fragulidis G, Pantiora E, Michalaki V, Kontis E, Primetis E, Vezakis A, et al. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient. J Oncol Pharm Pract 2017;10.78155217738325.","DOI":"10.1177\/1078155217738325"},{"key":"396_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CJI.0b013e31827807dd","volume":"36","author":"C Gaudy-Marqueste","year":"2013","unstructured":"Gaudy-Marqueste C, Monestier S, Franques J, Cantais E, Richard M-A, Grob J-J. A severe case of Ipilimumab-induced Guillain-Barr\u00e9 syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for Ipilimumab-induced colitis. J Immunother. 2013;36:77\u20138.","journal-title":"J Immunother"},{"key":"396_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","volume":"16","author":"B Liao","year":"2014","unstructured":"Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncol. 2014;16:589\u201393.","journal-title":"Neuro-Oncol"},{"key":"396_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/ana.10225","volume":"52","author":"JE Greenlee","year":"2002","unstructured":"Greenlee JE, Steffens JD, Clawson SA, Hill K, Dalmau J. Anti-Hu antibodies in Merkel cell carcinoma. Ann Neurol. 2002;52:111\u20135.","journal-title":"Ann Neurol"},{"key":"396_CR31","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","volume":"29","author":"AF Hottinger","year":"2016","unstructured":"Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol. 2016;29:806\u201312.","journal-title":"Curr Opin Neurol"},{"key":"396_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0002-9343(86)90047-1","volume":"80","author":"F Graus","year":"1986","unstructured":"Graus F, Elkon KB, Cordon-Cardo C, Posner JB. Sensory neuronopathy and small cell lung cancer: Antineuronal antibody that also reacts with the tumor. Am J Med. 1986;80:45\u201352.","journal-title":"Am J Med"},{"key":"396_CR33","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/j.1365-2559.2004.01792.x","volume":"44","author":"M-C Lopez","year":"2004","unstructured":"Lopez M-C, Pericay C, Agust\u00ed M, Martinez-Gallo M, Bordes R, Gelp\u00ed C. Merkel cell carcinoma associated with a paraneoplastic neurological syndrome. Histopathology. 2004;44:628\u20139.","journal-title":"Histopathology"},{"key":"396_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.lungcan.2017.07.026","volume":"111","author":"C Sculier","year":"2017","unstructured":"Sculier C, Bentea G, Ruelle L, Grigoriu B, Coureau M, Gorham J, et al. Autoimmune paraneoplastic syndromes associated to lung cancer: a systematic review of the literature: part 5: neurological auto-antibodies, discussion, flow chart, conclusions. Lung Cancer. 2017;111:164\u201375.","journal-title":"Lung Cancer"},{"key":"396_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S0165-5728(97)00124-0","volume":"79","author":"JJ Verschuuren","year":"1997","unstructured":"Verschuuren JJ, Dalmau J, Hoard R, Posner JB. Paraneoplastic anti-Hu serum: studies on human tumor cell lines. J Neuroimmunol. 1997;79:202\u201310.","journal-title":"J Neuroimmunol"},{"key":"396_CR36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/00042737-200504000-00010","volume":"17","author":"G Basilisco","year":"2005","unstructured":"Basilisco G, Gebbia C, Peracchi M, Velio P, Conte D, Bresolin N, et al. Cerebellar degeneration and hearing loss in a patient with idiopathic myenteric ganglionitis. Eur J Gastroenterol Hepatol. 2005;17:449.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"396_CR37","first-page":"109","volume":"4","author":"G Bassotti","year":"2011","unstructured":"Bassotti G, Villanacci V, Nejad MR. Chronic constipation: no more idiopathic, but a true neuropathological entity. Gastroenterol Hepatol Bed Bench. 2011;4:109\u201315.","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"396_CR38","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.3748\/wjg.v12.i29.4609","volume":"12","author":"G Bassotti","year":"2006","unstructured":"Bassotti G, Villanacci V. Slow transit constipation: a functional disorder becomes an enteric neuropathy. World J Gastroenterol. 2006;12:4609\u201313.","journal-title":"World J Gastroenterol"},{"key":"396_CR39","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama S, Remigis AD, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates Hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6:230ra45.","journal-title":"Sci Transl Med"},{"key":"396_CR40","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","volume":"35","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with Nivolumab and Ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. 2017;35:3807\u201314.","journal-title":"J Clin Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0396-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0396-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0396-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:43:51Z","timestamp":1601041431000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0396-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["396"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0396-9","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,31]]},"assertion":[{"value":"26 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The patient had provided informed consent for sharing his information on a research protocol approved by the University of Washington\/Fred Hutchison Cancer Research Center IRB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient and his wife had provided consent for the use of the medical information contained in this case report for research and publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SB reports institutional research (to UW) funding from Merck, Bristol Myers Squibb (BMS) and EMD-Serono. SB has participated in advisory boards, receiving honoraria, sponsored by Bristol Myers Squibb (BMS), Genentech and EMD-Serono. PN reports acting as a consultant for EMD Serono, Merck and Pfizer and his laboratory has received research funding from BMS & EMD Serono. The remaining authors declare that they have no competing financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"82"}}